078Efficacy and Safety of Baricitinib in Patients with Active Rheumatoid Arthritis and Inadequate Response to Tumour Necrosis Factor Inhibitors: Summary Results from the 24-Week Phase III RA-Beacon Study

Omid Zamani; Bernard Combe; Hans-Peter Tony; Juan Sanchez Burson; Hasan Tahir; Mikkel Oestergaard; Beatrice Augendre-Ferrante; Anke Beselin; Esbjorn Larsson; Marta Casillas; Josef Smolen

doi:10.1093/rheumatology/kew144.005

Retour

078Efficacy and Safety of Baricitinib in Patients with Active Rheumatoid Arthritis and Inadequate Response to Tumour Necrosis Factor Inhibitors: Summary Results from the 24-Week Phase III RA-Beacon Study

Article de revue scientifique

Avec comité de lecture

078Efficacy and Safety of Baricitinib in Patients with Active Rheumatoid Arthritis and Inadequate Response to Tumour Necrosis Factor Inhibitors: Summary Results from the 24-Week Phase III RA-Beacon Study

Omid Zamani, Bernard Combe, Hans-Peter Tony, Juan Sanchez Burson, Hasan Tahir, Mikkel Oestergaard, Beatrice Augendre-Ferrante, Anke Beselin, Esbjorn Larsson, Marta Casillas, …

Rheumatology (Oxford, England), Vol.55(suppl_1), p.i93-i93

01/04/2016

DOI: https://doi.org/10.1093/rheumatology/kew144.005

Indicateurs

1 Consultations de la notice

Détails

Titre: 078Efficacy and Safety of Baricitinib in Patients with Active Rheumatoid Arthritis and Inadequate Response to Tumour Necrosis Factor Inhibitors: Summary Results from the 24-Week Phase III RA-Beacon Study
Créateurs - sans rôle: Omid Zamani
Bernard Combe
Hans-Peter Tony
Juan Sanchez Burson
Hasan Tahir
Mikkel Oestergaard
Beatrice Augendre-Ferrante
Anke Beselin
Esbjorn Larsson
Marta Casillas
Josef Smolen
Détails de publication: Rheumatology (Oxford, England), Vol.55(suppl_1), p.i93-i93
Identifiants: 99233912009311
Unité académique: IGMM - Institut de Génétique Moléculaire de Montpellier
Langue: Anglais
Type de ressource: Article de revue scientifique